BRIEF: Burning Rock returns to revenue growth as loss narrows
Cancer screening company Burning Rock Biotech Ltd. (BNR.US) on Wednesday reported its revenue rose 0.8% in the third quarter year-on-year to 128.6 million yuan ($17.6 million), as it returned to…
Sinking Burning Rock faces de-listing. But could privatization bid come first?
The cancer-screening products maker is in danger of being forcibly delisted due to its sinking stock price, as income from its former top revenue source tumbles amid an industry crackdown…
FAST NEWS: Burning Rock’s cancer test gets breakthrough designation
The latest: Cancer screening company Burning Rock Biotech Ltd. (BNR.US) announced Sunday that its OverC multi-cancer detection blood test (MCDBT) has been granted breakthrough device designation by the China National…
Burning Rock narrows losses with drug research as new driver
The cancer testing company has finally reduced the flow of red ink and is generating a growing income stream from drug research services Key Takeaways: Burning Rock's net loss…
Burning Rock Localizes as Investors Grow Impatient
Cancer testing company reported a widening loss in the first quarter as it spent heavily to build up its localized business model of providing services through partner hospitals Key Takeaways:…
New Horizon’s Sales Surge as China Promotes Early Cancer Detection
Company’s first-mover advantage in at-home colorectal screening and China’s focus on early detection have turbocharged sales, though valuation remains frothy Key takeaways: New Horizon’s first-half revenues jumped more than fourfold,…
Pharmaron, I-Mab and Burning Rock Get Investor Validation From MSCI
Three up-and-coming Chinese pharma companies are among those included in latest adjustment for the index compiler’s China All Shares Index Key takeaways: MSCI’s addition of Pharmaron, I-Mab and Burning Rock…
RELATED ARTICLES
-
Sinking Burning Rock faces de-listing. But could privatization bid come first?
BNR.US
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Inaugural operating profit fails to lift 111 Inc.
YI.US
-
New Horizon Health launches probe into disputed sales figures
6606.HK
- Sunho Biologics gets green light for downsized IPO
- Bayzed joins IPO quest as medical rivalry heats up
